Jade Biosciences, Inc.
JBIOFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Jade Biosciences, Inc. Makes Money
No flow chart is shown because the available revenue and expense lines do not reconcile exactly. The reported financial history below remains available.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 6 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 26, 2026. The latest institutional report shown is dated Jun 30, 2025; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| Kovitz Investment Group Partners, LLC | 2025-06-30 | 24,210 | Not shown | SEC filing |
| Alamea Verwaltungs GmbH | 2025-06-30 | 204 | Not shown | SEC filing |
| Atlas Venture Life Science Advisors, LLC | 2025-03-31 | 1,799,232 | Not shown | SEC filing |
| SIMPLEX TRADING, LLC | 2025-03-31 | 1,571 | Not shown | SEC filing |
| NORTHERN TRUST CORP | 2025-03-31 | 109,217 | Not shown | SEC filing |
| ROYAL BANK OF CANADA | 2025-03-31 | 1,465 | Not shown | SEC filing |
| NEW YORK STATE COMMON RETIREMENT FUND | 2025-03-31 | 4,294 | Not shown | SEC filing |
| EverSource Wealth Advisors, LLC | 2025-03-31 | 30 | Not shown | SEC filing |
| BlackRock, Inc. | 2025-03-31 | 959,294 | Not shown | SEC filing |
| GOLDMAN SACHS GROUP INC | 2025-03-31 | 352,669 | Not shown | SEC filing |
| VANGUARD GROUP INC | 2025-03-31 | 1,066,996 | Not shown | SEC filing |
| TWO SIGMA INVESTMENTS, LP | 2025-03-31 | 204,791 | Not shown | SEC filing |
| GTS SECURITIES LLC | 2025-03-31 | 25,143 | Not shown | SEC filing |
| ACADIAN ASSET MANAGEMENT LLC | 2025-03-31 | 15,980 | Not shown | SEC filing |
| Russell Investments Group, Ltd. | 2025-03-31 | 32,395 | Not shown | SEC filing |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 2025-03-31 | 38,761 | Not shown | SEC filing |
| MILLENNIUM MANAGEMENT LLC | 2025-03-31 | 30,428 | Not shown | SEC filing |
| MORGAN STANLEY | 2025-03-31 | 699,438 | Not shown | SEC filing |
| Jefferies Financial Group Inc. | 2025-03-31 | 600,000 | Not shown | SEC filing |
| CWM, LLC | 2025-03-31 | 2,315 | Not shown | SEC filing |
- Each value is checked against Jade Biosciences, Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 20 rows: the value per share could not be confirmed against the share prices on file from within three months of the report date.
Filer report history
Two reports per filer, as filed. No change is calculated, because the data on file cannot confirm that both reports describe the same security.
- Alamea Verwaltungs GmbH: 204 shares reported 2025-03-31; 204 shares reported 2025-06-30.
- Kovitz Investment Group Partners, LLC: 26,514 shares reported 2025-03-31; 24,210 shares reported 2025-06-30.
- Legal & General Group Plc: 1,128 shares reported 2024-12-31; 1,128 shares reported 2025-03-31.
- TWO SIGMA ADVISERS, LP: 153,600 shares reported 2024-12-31; 291,800 shares reported 2025-03-31.
- Affinity Asset Advisors, LLC: 800,000 shares reported 2024-12-31; 800,000 shares reported 2025-03-31.
- TCG Crossover Management, LLC: 2,240,809 shares reported 2024-12-31; 2,240,809 shares reported 2025-03-31.
- BANK OF AMERICA CORP /DE/: 231,085 shares reported 2024-12-31; 246,914 shares reported 2025-03-31.
- CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM: 977 shares reported 2024-12-31; 977 shares reported 2025-03-31.
- DEUTSCHE BANK AG\: 720 shares reported 2024-12-31; 4,872 shares reported 2025-03-31.
- RA CAPITAL MANAGEMENT, L.P.: 9,192,092 shares reported 2024-12-31; 9,192,092 shares reported 2025-03-31.
- Verition Fund Management LLC: 94,635 shares reported 2024-12-31; 55,520 shares reported 2025-03-31.
- BANK OF MONTREAL /CAN/: 59,097 shares reported 2024-12-31; 59,097 shares reported 2025-03-31.
Showing the 12 most recent filer reports.
60 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Jade Biosciences, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2024-06-14 · Eldridge George A: Larger than 65 of the 67 other insider sales of Common Stock on file. SEC filing
- 2024-04-09 · GRAYZEL DAVID S.: Larger than 61 of the 67 other insider sales of Common Stock on file. SEC filing
- 2024-04-01 · Eldridge George A: Larger than 62 of the 67 other insider sales of Common Stock on file. SEC filing
- 2024-03-18 · Dake Benjamin T: Larger than all 67 other insider sales of Common Stock on file. SEC filing
- 2024-03-07 · Eldridge George A: Larger than 66 of the 67 other insider sales of Common Stock on file. SEC filing
- 2023-11-27 · Dake Benjamin T: Larger than 63 of the 67 other insider sales of Common Stock on file. SEC filing
- 2023-11-22 · NIVEN RALPH: Larger than 64 of the 67 other insider sales of Common Stock on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2025-05-16 | Frohlich Tom · Chief Executive Officer | Common Stock | P — Open market or private purchase | +6,000 | 7.40 | SEC filing |
| 2024-06-17 | RA Capital Healthcare Fund LP · Director, 10% owner | Common Stock | P — Open market or private purchase | +928,110 | 1.67 | SEC filing |
| 2024-06-14 | Verwijs Marinus · CHIEF TECHNICAL OFFICER | Common Stock | S — Open market or private sale | −10,600 | 25.00 | SEC filing |
| 2024-06-14 | Eldridge George A · SEE REMARKS | Common Stock | S — Open market or private sale | −15,000 | 25.03 | SEC filing |
| 2024-06-13 | Gillies Hunter · CHIEF MEDICAL OFFICER | Common Stock | S — Open market or private sale | −6,000 | 24.50 | SEC filing |
| 2024-05-17 | Gillies Hunter · CHIEF MEDICAL OFFICER | Common Stock | S — Open market or private sale | −86 | 21.86 | SEC filing |
| 2024-05-17 | Gillies Hunter · CHIEF MEDICAL OFFICER | Common Stock | S — Open market or private sale | −3,914 | 21.07 | SEC filing |
| 2024-05-16 | NOYES TIMOTHY P · CHIEF EXECUTIVE OFFICER | Common Stock | S — Open market or private sale | −8,707 | 21.52 | SEC filing |
Showing 8 of 12 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-25 | Eisner Mark · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +47,675 | SEC filing |
| 2026-06-09 | Lavelle Erin · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +34,843 | SEC filing |
| 2026-06-09 | Klein Lawrence Otto · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +34,843 | SEC filing |
| 2026-06-09 | Harwin Peter Evan · Director, 10% owner | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +34,843 | SEC filing |
| 2026-06-09 | CAIN CHRISTOPHER W. · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +34,843 | SEC filing |
| 2026-06-09 | DOBMEIER ERIC · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +34,843 | SEC filing |
| 2026-02-12 | Frohlich Tom · Chief Executive Officer | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +472,500 | SEC filing |
| 2026-02-12 | Balta Elizabeth · See Remarks | Common Stock | A — Grant, award, or other acquisition | +28,125 | SEC filing |
Showing 8 of 20 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2025-04-28 | RA Capital Healthcare Fund LP · 10% owner | Common Stock | J — Other acquisition or disposition | +1,062,326 | SEC filing |
Showing 1 of 1 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.